83results about "Immunological disorders" patented technology

The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.

The present invention calls utilized genes differentially expressed in target cells to design vaccines to generate an immune response. Unlike prior art methods that seek to identify antigenic proteins from phenotypic analysis, the subject method applies functional genomics for antigen identification. The method is exemplified herein and therefore provides compositions and methods for inducing an immune response against gp 100 melanoma cells and for inducing an immune response against HER-2+cells. Cancer vaccines and adoptive immunotherapeutic methods to treat and prevent conditions associated with the presence of these cells in a subject also are provided. The methods can be practiced by administering the appropriate gene or cancer vaccine, antibody, protein, polypeptide, antigen-presenting cell or immune effector cell.

The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

A health-care food in the form of soft-capsule, capsule, particle, tablet, or oral liquid for improving immunity and preventing and treating the injury of stomach mucosa is proportionally prepared from the oil of seabuckthorn fruit and the extract of propolis through mixing and shaping.

Disclosed are compounds based on lactone ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.

The water solution of bee glue includes the following steps: mixing bee glue and 95 % concentration alcohol solution via stirring, adding to water at 50-100 deg.c to obtain mixed water solution of bee glue and alcohol with alcohol content of 20-60 %, cooling to room temperature, letting stand and filtering; recovering alcohol and filtering to obtain filtrate; repeated alcohol dissolving and filtering of the filter residue and deposited matter to obtain filtrate; merging filtrate, concentration at 80 deg.c or adding water to density of 1.01-1.04, cooling, filtering to obtain the water solution of bee glue. The alcohol dissolving and water extracting process is simple, and the water solution of bee glue has high flavone content, no organic solvent and additive, low preparation cost and good biological effect. The water solution of bee glue may be used in preparing products for lowering blood sugar, lowering blood fat, resisting inflammation and regulating immunity.

Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with and responsive to modulation of the CB1 and/or CB2 receptor activity.

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

The invention discloses a ginsenoside-containing vegetable oil adjuvant and a preparation method and application thereof. The ginsenoside-containing vegetable oil adjuvant is characterized in that edible vegetable oil is used as the adjuvant oil; the ginsenoside-containing vegetable oil adjuvant comprises 10 to 100mu g/mL ginsenoside. According to the preparation method, the ginsenoside-containing vegetable oil is utilized for preparing vaccines, so that the vaccine safety can be greatly improved, and the potential hazard of the general mineral oil adjuvant on food hygiene is avoided; after being mixed, ginsenoside and vegetable oil play the effect of collaborating with the adjuvant, thus the valence of antibody is raised by 4.7 times, and the antibody level of the vaccines is also greatly improved; in addition, the prepared vaccine is high in mobility, convenient for inoculation, small in local stimulation, and thus relieving pain on animals; when the ginsenoside-containing vegetable oil adjuvant is applied to vaccine production, the existing production process is remained, and the method is simple and convenient.

The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises both the polysaccharides levan and inulin.

Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition and/or prognosis of various disorders.

The invention discloses a nutrition wine for nourishing yin and invigorating the kidney. The nutrition wine is prepared by pretreating the raw materials of 10-30 parts of Chinese yam, 20-40 parts of chrysanthemum, 5-15 parts of cinnamon, 10-20 parts of rhizoma polygonati, 8-12 parts of oyster, 20-30 parts of mulberry, 5-15 parts of white granulated sugar, 5-10 parts of caulis spatholobi and 900-1,000 parts of 42-degree distillate spirit; mixing and dipping; adjusting sugar; settling; and filtering. The nutrition wine has the functions of nourishing yin and yang, activating and enriching blood and building and invigorating body, can recuperate the subhealth and common symptoms of a human body, balance bodily functions and improve immunity and can be taken for a long time and has no side effect on the human body.

The invention provides an isodon amethystoides herbal tea drink and a preparation method thereof. The herbal tea drink is characterized by being prepared from the following traditional Chinese medicine materials in parts by weight: 15 to 20 parts of isodon amethystoides, 5 to 15 parts of oldenlandia diffusa, 10 to 15 parts of sculellaria barbata, 3 to 10 parts of polygonum cuspidatum, 3 to 10 parts of honeysuckle, 7 to 11 parts of salvia miltiorrhiza, 10 to 15 parts of astragalus membranaceus, 3 to 10 parts of tea leaves, 7 to 11 parts of radix bupleuri and 2 to 5 parts of Chinese dates. Based on the innovation of medicine selection, a formula, proportions and the preparation method, the functions of the isodon amethystoides for clearing away heat and toxic materials, resisting bacteria and diminishing inflammation, cooling blood and scattering stasis, harmonizing stomach and protecting liver, relieving cough and asthma, regulating immunity and the like are fully exerted while the defect of gastrointestinal discomfort caused by taking the isodon amethystoides for a long time is overcome at the same time, so that the herbal tea drink has various functions for preventing and treating throat diseases, respiratory tract diseases, digestive tract diseases, gastrointestinal diseases and other diseases, low immunity and the like which are caused by haze and environmental pollution.

The invention discloses a preparation method of high-purity gynostemma pentaphylla total saponin for veterinary drugs. The preparation method is characterized in that a medicinal gynostemma pentaphylla total saponin medicinal material is used as a raw material, and the high-purity target product, namely the gynostemma pentaphylla total saponin for the veterinary drug, is obtained by high-efficiency extraction and separation on the basis of combination of technologies such as continuous countercurrent supersonic wave extraction, ceramic membrane microfiltration and macroporous resin adsorption separation with a conventional solvent reflux extraction principle. The preparation method has the advantages that the product purity and the product yield are improved, the product quality and the high quality are stabilized, the production cost is reduced, the requirements on the development of the high-purity gynostemma pentaphylla total saponin for the veterinary drugs and highly-processed products of gynostemma pentaphylla total saponin are satisfied, the production process is in line with environmental protection requirements, and the difficulty in the coordination of working procedures such as extraction, solvent recovery, enrichment and purification occurring in the volume production process of the gynostemma pentaphylla total saponin for the veterinary drugs is solved through the continuous improvement of the technology and the adjustment of technological processes and technical parameters.

The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.

The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.

The invention belongs to the field of daily chemical products, particularly relates to bacteriostatic foot powder and a preparation method thereof, and provides bacteriostatic foot powder. The bacteriostatic foot powder comprises the following components in percentages by weight: alkannin 1-3%, cinnaldehydrum 2-4%, berberine 1-5%, patchouli alcohol 2-4%, menthol 1-2%, alkyl glycoside 2-6%, tea saponin 0.5-1.5%, dipotassium glycyrrhizinate 1-3%, a deodorant 2-10%, ethanol 5-25% and corn flour 36.5-82.5%. The bacteriostatic foot powder not only can effectively improve foot hyperhidrosis and prevent and treat foot odour, but also can inhibit bacteria, diminish inflammation and resist allergy, and effectively treats tinea pedis. Meanwhile, the provided bacteriostatic foot powder is gentle in property, and is safe and non-irritant.